(Q42244128)

English

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection

scientific article published on 14 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Clostridium difficile

0 references

object named as

J Freeman

5

0 references

author name string

C H Chilton

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

G S Crowther

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

S D Baines

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

S L Todhunter

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

H H Locher

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

A Athanasiou

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

M H Wilcox

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

14 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

697-705

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

The changing epidemiology of Clostridium difficile infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Economic healthcare costs of Clostridium difficile infection: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Fidaxomicin versus vancomycin for Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Reduced susceptibility of Clostridium difficile to metronidazole.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Validation of a Three-Stage Compound Continuous Culture System for Investigating the Effect of Retention Time on the Ecology and Metabolism of Bacteria in the Human Colon

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Penetration of clindamycin phosphate into the abnormal human biliary tract

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKT411

21 January 2018

Identifiers

10.1093/JAC/DKT411

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42244128&oldid=1939783613"